vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $83.1M, roughly 1.0× PROCEPT BioRobotics Corp). On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 9.4%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 4.3%).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

AMAL vs PRCT — Head-to-Head

Bigger by revenue
AMAL
AMAL
1.0× larger
AMAL
$85.2M
$83.1M
PRCT
Growing faster (revenue YoY)
PRCT
PRCT
+10.8% gap
PRCT
20.2%
9.4%
AMAL
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
4.3%
AMAL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AMAL
AMAL
PRCT
PRCT
Revenue
$85.2M
$83.1M
Net Profit
$-31.6M
Gross Margin
64.9%
Operating Margin
39.0%
-4.1%
Net Margin
-38.1%
Revenue YoY
9.4%
20.2%
Net Profit YoY
-27.9%
EPS (diluted)
$0.88
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$85.2M
$76.4M
Q3 25
$85.6M
$83.3M
Q2 25
$80.9M
$79.2M
Q1 25
$77.0M
$69.2M
Q4 24
$77.9M
$68.2M
Q3 24
$81.0M
$58.4M
Q2 24
$78.5M
$53.4M
Net Profit
AMAL
AMAL
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-29.8M
Q3 25
$26.8M
$-21.4M
Q2 25
$26.0M
$-19.6M
Q1 25
$25.0M
$-24.7M
Q4 24
$-18.9M
Q3 24
$27.9M
$-21.0M
Q2 24
$26.8M
$-25.6M
Gross Margin
AMAL
AMAL
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
AMAL
AMAL
PRCT
PRCT
Q1 26
-4.1%
Q4 25
39.0%
-40.6%
Q3 25
42.9%
-27.8%
Q2 25
43.8%
-28.0%
Q1 25
45.1%
-39.7%
Q4 24
42.4%
-28.9%
Q3 24
47.2%
-38.4%
Q2 24
45.6%
-50.3%
Net Margin
AMAL
AMAL
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-39.1%
Q3 25
31.3%
-25.7%
Q2 25
32.1%
-24.7%
Q1 25
32.5%
-35.8%
Q4 24
-27.6%
Q3 24
34.5%
-35.9%
Q2 24
34.1%
-48.0%
EPS (diluted)
AMAL
AMAL
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.88
$-0.54
Q3 25
$0.88
$-0.38
Q2 25
$0.84
$-0.35
Q1 25
$0.81
$-0.45
Q4 24
$0.78
$-0.34
Q3 24
$0.90
$-0.40
Q2 24
$0.87
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$291.2M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$794.5M
$347.7M
Total Assets
$8.9B
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$291.2M
$286.5M
Q3 25
$115.5M
$294.3M
Q2 25
$171.1M
$302.7M
Q1 25
$65.7M
$316.2M
Q4 24
$60.7M
$333.7M
Q3 24
$149.2M
$196.8M
Q2 24
$58.0M
$214.1M
Total Debt
AMAL
AMAL
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
AMAL
AMAL
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$794.5M
$365.9M
Q3 25
$775.6M
$380.3M
Q2 25
$754.0M
$385.8M
Q1 25
$736.0M
$389.2M
Q4 24
$707.7M
$402.2M
Q3 24
$698.2M
$241.2M
Q2 24
$646.0M
$251.8M
Total Assets
AMAL
AMAL
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$8.9B
$508.1M
Q3 25
$8.7B
$511.5M
Q2 25
$8.6B
$513.1M
Q1 25
$8.3B
$519.4M
Q4 24
$8.3B
$534.0M
Q3 24
$8.4B
$374.1M
Q2 24
$8.3B
$374.4M
Debt / Equity
AMAL
AMAL
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
PRCT
PRCT
Operating Cash FlowLast quarter
$135.8M
Free Cash FlowOCF − Capex
$134.4M
FCF MarginFCF / Revenue
157.8%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
PRCT
PRCT
Q1 26
Q4 25
$135.8M
$-10.3M
Q3 25
$39.5M
$-6.6M
Q2 25
$24.9M
$-15.0M
Q1 25
$34.2M
$-17.0M
Q4 24
$124.1M
$-32.4M
Q3 24
$35.8M
$-18.8M
Q2 24
$28.0M
$-15.7M
Free Cash Flow
AMAL
AMAL
PRCT
PRCT
Q1 26
Q4 25
$134.4M
$-12.2M
Q3 25
$38.3M
$-9.5M
Q2 25
$24.2M
$-17.8M
Q1 25
$32.5M
$-18.8M
Q4 24
$122.3M
$-33.6M
Q3 24
$35.2M
$-19.0M
Q2 24
$27.8M
$-16.8M
FCF Margin
AMAL
AMAL
PRCT
PRCT
Q1 26
Q4 25
157.8%
-15.9%
Q3 25
44.7%
-11.4%
Q2 25
29.9%
-22.5%
Q1 25
42.2%
-27.2%
Q4 24
157.0%
-49.2%
Q3 24
43.4%
-32.6%
Q2 24
35.4%
-31.4%
Capex Intensity
AMAL
AMAL
PRCT
PRCT
Q1 26
Q4 25
1.6%
2.4%
Q3 25
1.4%
3.4%
Q2 25
0.9%
3.5%
Q1 25
2.3%
2.7%
Q4 24
2.3%
1.7%
Q3 24
0.7%
0.4%
Q2 24
0.3%
2.0%
Cash Conversion
AMAL
AMAL
PRCT
PRCT
Q1 26
Q4 25
Q3 25
1.47×
Q2 25
0.96×
Q1 25
1.37×
Q4 24
Q3 24
1.28×
Q2 24
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMAL
AMAL

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons